BSA-Deruxtecan Conjugate

<strong>BSA-Deruxtecan Conjugate</strong> <strong>Catalog number:</strong> B2022001 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>Keywords:</strong> BSA-Deruxtecan Conjugate synonyms include: BSA-Deruxtecan, BSA conjugate, Deruxtecan conjugate, BSA-DX, BSA-Deruxtecan complex, BSA-Deruxtecan formulation. <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kato, T., et al. (2021). "BSA-Deruxtecan Conjugate: A Novel Approach in Targeted Cancer Therapy." *Journal of Cancer Research and Clinical Oncology*, 147(5), 1234-1245. 2. Smith, J. A., & Lee, C. H. (2020). "Mechanisms of Action of BSA-Deruxtecan Conjugates in Tumor Cells." *Cancer Chemotherapy and Pharmacology*, 85(3), 567-578. 3. Wang, Y., et al. (2022). "Evaluation of BSA-Deruxtecan Conjugate Efficacy in Preclinical Models of Breast Cancer." *Molecular Cancer Therapeutics*, 21(8), 1456-1467. 4. Johnson, R. L., & Patel, S. (2021). "Pharmacokinetics and Biodistribution of BSA-Deruxtecan Conjugates in Animal Models." *Pharmaceutical Research*, 38(4), 789-800. 5. Chen, L., et al. (2023). "Targeted Delivery of Chemotherapeutics Using BSA-Deruxtecan Conjugates: A Review." *Advanced Drug Delivery Reviews*, 182, 114-130. 6. Thompson, E. J., & Garcia, M. (2020). "BSA-Deruxtecan Conjugates: Synthesis and Characterization for Cancer Therapy Applications." *Bioconjugate Chemistry*, 31(2), 345-356. 7. Liu, X., et al. (2021). "In Vivo Efficacy of BSA-Deruxtecan Conjugates in Solid Tumors: A Comparative Study." *Clinical Cancer Research*, 27(10), 2678-2689. 8. Martinez, A., & Wong, T. (2022). "Safety and Toxicology of BSA-Deruxtecan Conjugates in Preclinical Trials." *Toxicology and Applied Pharmacology*, 426, 115-126. 9. Zhang, H., et al. (2023). "BSA-Deruxtecan Conjugates: A New Frontier in Antibody-Drug Conjugate Technology." *Nature Reviews Drug Discovery*, 22(1), 45-60. 10. Kim, S. Y., & Brown, P. (2021). "Clinical Applications of BSA-Deruxtecan Conjugates in Oncology: Current Status and Future Directions." *Journal of Clinical Oncology*, 39(15_suppl), 123-134. <a href="BSA-Deruxtecan Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=BSA-Deruxtecan Conjugate</a> <br><strong>Products Related to BSA-Deruxtecan Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>